Jelrix (autologous cartilage-derived articular chondrocytes, in-vitro expanded)
ATMP
- Region
- 🇪🇺 EU
- Active substance
- autologous cartilage-derived articular chondrocytes, in-vitro expanded
- Company
- TETEC Tissue Engineering Technologies AG
- Status
- Application withdrawn
- Therapeutic area
- Knee Injuries; Cartilage Diseases; Knee Joint
- CHMP opinion
- Thu 24 Jul 2025
- Designations
- ATMP
- Application
- EMEA/H/C/004594
- ATC
- M09AX02
- Official record
- www.ema.europa.eu
Indication
Repair of symptomatic, localised, full-thickness cartilage defects of the knee joint grade III or IV
Regulatory milestones
Tue 11 Nov 2025🇪🇺 Application withdrawn (EU)
Jelrix (autologous cartilage-derived articular chondrocytes, in-vitro expanded): EU application withdrawn
Follow Jelrix
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.